ArticleCurrent trends in medical diagnostic methods2025
Utility of different anti-IgG antibodies in recognition of punctate (powdery) podocyte staining by immunofluorescence in patients with diffuse podocyte foot process effacement.
Article in Current trends in medical diagnostic methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Circulating anti-nephrin autoantibodies recently were recognized as a possible pathogenic factor in patients with steroid-resistant minimal change disease. In a kidney biopsy, these patients have punctate ("powdery") staining in the podocytes by immunofluorescence. Previously published data described such pattern of staining by using anti-IgG Dako antibody. In the routine practice, different laboratories use different anti-IgG antibodies from a variety of vendors. The aim of this work was to compare the ability to recognize the punctate staining in the podocyte by two different anti-IgG antibodies (Dako and Kent) that are in use in our routine renal pathology practice. Our data indicates that both anti-IgG antibodies recognize the punctate ("powdery) staining in the podocytes in a subset of patients with minimal change disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.